Jonas E. Salk—Discoverer of a Vaccine Against Poliomyelitis

Poliomyelitis Vaccine

The Epidemiology of poliomgelitis has been investigated in our country Pasteur Institute; the incidence of Poliomgelitis, after the age of 4 years i's rare, in Iran.  Passive antibody of maternal origin do not interfere with production of active antibody after immunization.  Inactivated Polio Vaccine (salk) has been effective in reducing the incidence of poliomge­litis by approximately 90 per ...

Vaccine-associated paralytic poliomyelitis.

In the wake of the World Health Organization’s (WHO) program to eradicate poliomyelitis globally by the end of the year 2000 (in 1997 only 5,186 cases were reported world-wide), attention has focussed on the importance of good surveillance of acute flaccid paralysis, which is essential for a country to qualify for being declared polio-free, and on the occurrence of vaccine–associated paralytic ...

Stability Study of Razi Trivalent and Monovalent Oral Poliomyelitis Vaccine

Stability studies play a critical role in assuring product quality at all points in the vaccine life cycle. These studies used to determine vaccine expiry date and vaccine efficacy. Accelerated stability and long term stability study performed for three batches of trivalent oral poliomyelitis vaccine (OPV) and three batches of monovalent OPV (type1) manufactured by Razi institute. After samplin...

Active Immunization against Poliomyelitis

1. A single intracutaneous inoculation with a subinfective dose of the virus of poliomyelitis produces considerable immunity. 2. Virus-serum combinations produce an appreciable immunity, providing just sufficient serum is used to protect the animal from paralysis. If there is an excess of serum, the degree of immunity is considerably reduced.

The Fight against Poliomyelitis